---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-24-000007"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:39:23.464685+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment

## Summary
- FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).
- Tyvaso revenue grew 41% to $1.23B; Tyvaso DPI rose 362% to $731M.
- Q4 2023 revenue $614.7M (+25% YoY), net income $217.1M (diluted EPS $4.36).
- Filed lawsuit against FDA alleging agency improperly allowed Liquidia to amend pending NDA for PH-ILD, avoiding a 30-month stay of approval.
- Litigation seeks to enforce Hatch-Waxman patent infringement stay pending resolution of separate patent case against Liquidia.

## SEC filing metadata
- accession: 0001082554-24-000007
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/uthr-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-24-000007
- JSON: https://secwatch.observer/filing/0001082554-24-000007.json
- Plain text: https://secwatch.observer/filing/0001082554-24-000007.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported three months ended December 31, 2023 results: revenue $614.7 million, net income $217.1 million, EPS $4.36 per diluted share.
  - Period: three months ended December 31, 2023
  - Revenue: $614.7 million
  - Net income: $217.1 million
  - EPS: $4.36 per diluted share
  - Result: reported results
  source text: Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Total revenues $ 614.7 $ 491.5 $ 2,327.5 $ 1,936.3 Net income $ 217.1 $ 132.1 $ 984.8 $ 727.3 Net income, per basic share $ 4.62 $ 2.88 $ 21.04 $ 15.98 Net income, per diluted share $ 4.36 $ 2.67 $ 19.81 $ 15.00
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm
- Earnings Releases
  UNITED THERAPEUTICS Corp reported year ended December 31, 2023 results: revenue $2,327.5 million, net income $984.8 million, EPS $19.81 per diluted share.
  - Period: year ended December 31, 2023
  - Revenue: $2,327.5 million
  - Net income: $984.8 million
  - EPS: $19.81 per diluted share
  - Result: reported results
  source text: (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.